PBAC to Weigh GP Initiation of Romosozumab
The Pharmaceutical Benefits Advisory Committee will consider letting GPs start osteoporosis patients on romosozumab, not just continue treatment.
Updated on Nov. 19, 2026 in Health

Live Poll
Do you think getting timely specialist treatment is getting easier or harder?
The Pharmaceutical Benefits Advisory Committee is set to discuss allowing GPs to initiate romosozumab, sold as Evenity, for severe established osteoporosis at its March 2027 meeting. Currently GPs can continue treatment once a consultant physician has started it, but cannot start it themselves.
Why it matters
Proposed changes would reduce the need for specialists to approve initiation of treatment for patients with severe osteoporosis. The move comes as poor bone health affects an estimated 6.2 million Australians over 50.
An estimated 6.2 million Australians over 50 are affected by poor bone health, a figure projected to rise 23% to 7.7 million over the next seven years. The stub does not confirm whether the committee will support the proposed change.
The players
Pharmaceutical Benefits Advisory Committee
The committee advises on which medicines are listed on the Pharmaceutical Benefits Scheme, and its recommendations shape subsidised prescribing across Australia.
Professor Dimity Pond
Professor Dimity Pond is a general practice academic quoted in this story as a commentator on the proposed changes.
The details
Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that suppresses bone formation, and is given as two 105 mg subcutaneous injections once a month for 12 months. Current guidelines recommend it as first-line therapy for very high-risk osteoporosis in post-menopausal women and men, and telephone or online authority is required to prescribe it.
Timeline
March 2027: Pharmaceutical Benefits Advisory Committee to discuss romosozumab listing changes.
Next seven years: Projected 23% rise in Australians with poor bone health.
2033: A fracture is estimated to occur every 30 seconds.
Big Picture
The proposal sits within the Pharmaceutical Benefits Scheme listing process, where the Pharmaceutical Benefits Advisory Committee reviews prescribing criteria for subsidised medicines. It would extend prescribing rights that GPs already hold for continuing romosozumab to starting it as well.
If the change proceeds, patients with severe osteoporosis could have romosozumab started by their GP rather than waiting for a specialist referral and approval. Access to the treatment would depend on the committee's decision and on meeting the telephone or online authority requirements.
The takeaway
Patients with poor bone health should discuss osteoporosis treatment options with their doctor, since current criteria and any future listing changes determine who can prescribe romosozumab. Keeping informed about the committee's March 2027 decision will show whether starting treatment in general practice becomes an option.
What happens next
The Pharmaceutical Benefits Advisory Committee will discuss the proposed change to romosozumab listing at its March 2027 meeting.
Further reading
Explore more broad health coverage in Health — General for context on how medicine access rules are set in Australia.
Source note: This article includes information reported by Racgp.
Live Poll
Do you think getting timely specialist treatment is getting easier or harder?






